IP Library Granted Patent US 10,525,097
Granted Patent B2
US 10,525,097 · App. 15/353,863 · Granted Jan 7, 2020

Methods for the treatment of glaucoma and age-related macular degeneratiion by a peptide D-TRP-AIB

Inventor: Hermann Russ (Altendorf, CH)
Assignee: Ramot at Tel Aviv University Ltd
A61K38/07A61K9/0048A61K38/06A61K45/06A61B3/102A61B3/1233A61B3/1241A61K38/05A61K47/02A61K2300/00A61P27/02C07K5/06078C07K5/06156C07K5/0812C07K14/4703C07K14/4711G06T5/50G06T7/0016G06T7/337G06T2207/10101G06T2207/20224G06T2207/30041
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,525,097
App. No.
15/353,863
Granted
Jan 7, 2020
Kind
B2
Abstract

Methods for the prevention and treatment of ocular disorders, in particular glaucoma, through blocking the toxic effects of β-amyloid (Aβ) derivatives, and pharmaceutical compositions for effecting such prevention and treatment thereof.

Claims (6)

1. A method of treating an optical condition associated with (β-amyloid (Aβ) toxicity, said optical condition being glaucoma or age-related macular degeneration (AMD), the method comprising the step of administering to an eye of a living animal, including a human, a therapeutically effective amount of a composition comprising a peptide D-Trp-Aib (SEQ ID NO: 30), wherein the composition is formulated in the form of eye drops, thereby inhibiting Aβ formation and/or the occurrence of said Aβ in the eye of the living animal with glaucoma or AMD, which is effective for alleviation of the condition.

2. The method of claim 1 , wherein glaucoma is selected from the group consisting of primary angle-closure glaucoma, secondary open-angle glaucoma, wide-angle glaucoma, steroid-induced glaucoma, traumatic glaucoma, secondary angle-closure glaucoma, and neovascular glaucoma.

3. The method of claim 1 , wherein the composition comprises the peptide D-Trp-Aib (SEQ ID NO: 30) in combination with at least one additional pharmaceutical agent for treating the optical condition, wherein the combination of the peptide and the at least one additional pharmaceutical agent is effective in treating the condition.

4. The method of claim 3 , wherein the at least one additional pharmaceutical agent is selected from the group consisting of anti-glaucoma drugs, antibiotics, anti-inflammatory drugs, steroids, anti-allergic drugs and artificial tear fluid.

5. The method of claim 3 , wherein the at least one additional pharmaceutical agent is selected from the group consisting of acetazolamide, diclofenamide, carteolol, timolol, metipranolol, betaxolol, pindolol, lcvobunolol, brimonidine, clonidine, pilocarpine, carbachol, dipivefrine, apraclonidine, brinzolamide, dorzolaminde, bimatoprost, travaprost, latanoprost, chlortetracycline, ciprofloxacine, ofloxacinc, fusidinic acid, gentalnicine, kanamycine, levolloxacine, lomefloxacine, oxytetracycline, natamycins, azidamfenicole, chloramphenicole, tobramycine, erythromycine, polymyxin-B, acaclovir, trifluridine, betamethasone, dexamethasone, fluorometholone, hydrocortisone, prednisolone, rimexolone, cromoglicate, azelastine, lodoxamide, emedastine, nedocromile, levocabastine, olopatadinea, ketotifene, hypromellose, carbomere, hyaluronate, carmellose, hypromellose, povidone, hyetellose, polivinylalcohole, dexpanthenole, tetryzoline, troxerutine, tramazoline, naphazoline, xylometazoline, phenylephrine and antazoline.

6. The method of claim 1 , wherein the composition is administered once a day, twice a day or three times a day.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2019
From: RUSS, HERMANN
To: RAMOT AT TEL AVIV UNIVERSITY LTD
Reel/Frame 051072/0035 →
Priority Claims (1)
FR 07 253904 · Oct 2, 2007 · national
Continuity (3)
Continuation 12733270
Provisional Application 60965650 · Aug 21, 2007
Related Publication 20170065664A1 · Mar 9, 2017